KANTAR HEALTH BLOG

ASCO Annual Meeting 2017 - Data were presented on LATITUDE, a randomized Phase III trial comparing Zytiga/prednisone plus androgen deprivation therapy (ADT) versus placebos plus ADT in newly-diagnosed high-risk metastatic hormone-naive prostate cancer (mHSPC). Based on these data, Zytiga will likely become the new standard of care for high-risk mHSPC patients. As the discussant, Eric Small, MD, stated, “LATITUDE was a profoundly positive study.”

ASCO Annual Meeting 2017 - If Lenvima is used in the first-line, will physicians need to wait to use Stivarga in the third-line setting after Nexavar is offered in the second-line? Could physicians’ preference to use first-line Nexavar and second-line Stivarga impact where Lenvima might be offered?

ASCO Annual Meeting 2017 - Given the hurdles, the data is only “semi-sweet”: good enough for regulatory approval, but the toxicities seen in MONARCH 2, and abemaciclib’s eventual third-to-market introduction might cause physicians to question when to offer the agent.

This blog reviews how laughter can be used as a tool in qualitative market research to foster connections and get deeper insights.

Colleen discusses the importance of engaging Health Activators in healthcare market research.